Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells.
暂无分享,去创建一个
R. Morgan | T. Hawley | R. Hawley | A. Ramezani | M. Moayeri
[1] S. Pipe,et al. 1 Bioengineering of Coagulation Factor VIII for Improved Secretion , 2004, Pediatric Research.
[2] T. Rabbitts,et al. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. , 2004, The New England journal of medicine.
[3] R. Donahue,et al. Induction of transgene-specific immunological tolerance in myeloablated nonhuman primates using lentivirally transduced CD34+ progenitor cells. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] R. Hawley,et al. Integrative molecular and developmental biology of adult stem cells , 2003, Biology of the cell.
[5] Cameron S. Osborne,et al. LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.
[6] A. Ganser,et al. Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction , 2003, Gene Therapy.
[7] M. Denaro,et al. Engraftment of retroviral EGFP-transduced bone marrow in mice prevents rejection of EGFP-transgenic skin grafts. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] Bing Liu,et al. Isolation of Mouse Marrow Mesenchymal Progenitors by a Novel and Reliable Method , 2003, Stem cells.
[9] T. Hawley,et al. Performance- and safety-enhanced lentiviral vectors containing the human interferon-β scaffold attachment region and the chicken β-globin insulator , 2003 .
[10] K. Pasi,et al. Haemophilias A and B , 2003, The Lancet.
[11] I. Verma,et al. Efficient production of human FVIII in hemophilic mice using lentiviral vectors. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[12] R. Hawley,et al. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. , 2003, Current gene therapy.
[13] F. Luyten,et al. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long‐terminal repeats , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[14] J. Cancelas,et al. Myeloablation enhances engraftment of transduced murine hematopoietic cells, but does not influence long-term expression of the transgene , 2002, Gene Therapy.
[15] C. Herder,et al. Generation and characterization of human hematopoietic cell lines expressing factor VIII. , 2002, Journal of hematotherapy & stem cell research.
[16] A. Mortellaro,et al. Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.
[17] A. Fischer,et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.
[18] N. Giri,et al. In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. , 2001, Human gene therapy.
[19] R. Hawley. Progress toward vector design for hematopoietic stem cell gene therapy. , 2001, Current gene therapy.
[20] K. High. Gene transfer as an approach to treating hemophilia. , 2001, Circulation research.
[21] D. Heim,et al. Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency , 2000, Immunological reviews.
[22] T. Hawley,et al. Lentiviral vectors for enhanced gene expression in human hematopoietic cells. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[23] J. Tisdale,et al. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] I. London,et al. Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[25] T. VandenDriessche,et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice. , 2000, Human gene therapy.
[26] Jiahua Qian,et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. , 2000, Blood.
[27] P. Watkins,et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. , 1999, Experimental hematology.
[28] S. Bidlingmaier,et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] L. Cheng,et al. Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny. , 1998, Blood.
[30] R. Morgan,et al. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[31] R. Kaufman,et al. Mutagenesis of a Potential Immunoglobulin-binding Protein-binding Site Enhances Secretion of Coagulation Factor VIII* , 1997, The Journal of Biological Chemistry.
[32] R. Mulligan,et al. Versatile Retrovirus Vector Systems for Regulated Gene Expression In Vitro and In Vivo , 1997, Molecular medicine.
[33] J. Leonard,et al. Retroviral Vectors for Production of Interleukin‐12 in the Bone Marrow to Induce a Graft‐Versus‐Leukemia Effect a , 1996, Annals of the New York Academy of Sciences.
[34] J. Leonard,et al. Thrombopoietic potential and serial repopulating ability of murine hematopoietic stem cells constitutively expressing interleukin 11. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[35] H. Malech,et al. Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy. , 1996, Blood.
[36] H. Pircher,et al. Prevention of autoimmune disease by retroviral-mediated gene therapy. , 1995, Journal of immunology.
[37] R. Morgan,et al. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. , 1995, Human gene therapy.
[38] A. Berns,et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[39] T. Hawley,et al. Versatile retroviral vectors for potential use in gene therapy. , 1994, Gene therapy.
[40] A. Giles,et al. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. , 1993, Blood.
[41] A. van der Eb,et al. Toward Gene Therapy in Haemophilia A: Retrovirus-Mediated Transfer of a Factor VIII Gene into Murine Haematopoietic Progenitor Cells , 1992, Thrombosis and Haemostasis.
[42] R. Kaufman,et al. Retroviral-mediated transfer and amplification of a functional human factor VIII gene. , 1990, Blood.
[43] T. Hawley,et al. Comparative analysis of retroviral vector expression in mouse embryonal carcinoma cells. , 1989, Plasmid.
[44] A. Dorner,et al. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. , 1988, The Journal of biological chemistry.
[45] H. Karasuyama,et al. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors , 1988, European journal of immunology.
[46] T. Hawley,et al. Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[47] C. Croce,et al. DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[48] H. Nakauchi,et al. Simplified retroviral vector gcsap with murine stem cell virus long terminal repeat allows high and continued expression of enhanced green fluorescent protein by human hematopoietic progenitors engrafted in nonobese diabetic/severe combined immunodeficient mice. , 2001, Human gene therapy.
[49] J. Dick,et al. Expansion of human cord blood CD34(+)CD38(-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. , 2000, Blood.
[50] R. Mulligan,et al. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells. , 1996, Gene therapy.
[51] L. Hoyer. Medical progress : hemophilia A , 1994 .
[52] T. Hawley,et al. Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. , 1992, Journal of immunological methods.
[53] M. Haine,et al. Van Damme A. , 1986 .